Bioheart Set to Present at International Academy of Cardiology, 16th World Congress on Heart Disease, Annual Scientific Sessions 2011

Jun 16, 2011, 17:20 ET from Bioheart, Inc.

SUNRISE, Fla., June 16, 2011 /PRNewswire/ -- Bioheart, Inc. (OTC Bulletin Board: BHRT) is one of the Emerging Biotech Presenters at the International Academy of Cardiology, 16th World Congress on Heart Disease, Annual Scientific Sessions– July 23rd-26th in Vancouver at the Hyatt Regency Vancouver.  Howard J. Leonhardt, Bioheart's Founder and Chief Technology Officer, will be presenting on Myoblast Transplantation for Heart Repair, a Review of the State of Field. His presentation will take place on Monday, July 25th, at 3:30 pm in Hall D Ballroom of the Hyatt Regency.

About Bioheart, Inc.

Bioheart is focused on completing its Phase II/III MARVEL study for MyoCell in treating advanced heart failure.  The product candidate has been in clinical trials since May of 2001.  The company believes, after 10 years of clinical trials that followed pre-clinical studies dating to 1988, that it may be on the final leg towards qualifying to apply for a biologics license approval FDA panel review.  Approximately 130 patients more are needed to be completed in the randomized, double blinded, placebo controlled MARVEL Phase II/III Part II study.  In the MARVEL Phase II/III Part I study the performance of MyoCell was nearly 500% above its primary end point goal of 16 meters improvement in exercise capacity testing.  Bioheart MyoCell patients came in at 91.7 meters improvement while placebo injected patients had a 4 meter decline. Both groups were also on HFSA recommended optional CHF drugs.  This small study MARVEL Phase II/III Part I data correlated well with the data gathered on nearly 300 patients in various myoblast transplantation to treat heart failure studies since 2000 and pre-clinical studies by Bioheart Scientific Advisory Board Members since 1988.  This led to design and launch of the larger scale MARVEL Phase II/III  Part II study.

MyoCell is a clinical muscle-derived stem cell therapy designed to populate regions of scar tissue within a patient's heart with new living cells for the intended purpose of improving cardiac function and quality of life in chronic heart failure patients.

For more information on Bioheart, visit

Forward-Looking Statements: Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as "may," "will," "to," "plan," "expect," "believe," "anticipate," "intend," "could," "would," "estimate," or "continue" or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements.

Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Also, forward-looking statements represent our management's beliefs and assumptions only as of the date hereof. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.

The Company is subject to the risks and uncertainties described in its filings with the Securities and Exchange Commission, including the section entitled "Risk Factors" in its Annual Report on Form 10-K for the year ended December 31, 2010, and its Quarterly Report on Form 10-Q for the quarter ended March 31, 2011.

SOURCE Bioheart, Inc.